Mattawan, MI (November 20, 2009) – Ophthy-DS responds to an increasing demand for opthalmic toxicological services and access to a wider range of regulated species by forming an alliance with MPI Research, a toxicoloy CRO that company that assists pharmaceutical and biotech companies in bringing their ocular drugs and devices to market. Jeffrey Jamison, PhD, will direct aspects of ophthalmic research, from preclinical studies including in vivo analytical assays and treatment evaluation to early clinical research and post-approval studies. Remaining the CEO of Ophthy-DS, Dr. Jamison will also direct an ocular lab at MPI Research that will complement current ocular toxicology assays while developing customized animal models of various opthalmic conditions. Models currently offered and under early development include:

  • Dry and Wet Age-Related Macular Degeneration (AMD)
    • Light damage/ photo oxidative stress
    • Laser-induced Choroidal Neo-Vascularization (CNV)
    • Vascular Endothelial Growth Factor (VEGF)-induced retinal leakage
    • Genetic mutants with or without environmental modification
  • Diabetes
    • Streptozotocin (STZ)-Induced diabetes
  • Dry Eye
    • Scopolamine induced lacrimal gland dysfunction

According to Dr. Glenn Smits, Director of the Discovery Center at MPI Research, “Dr. Jamison is a recognized expert in the field of electroretinography and animal model development. Under his leadership, MPI Research can offer the very best in ocular drug and device development services. Our excellent team of discovery scientists is eager to work with Jeff as we partner with our pharmaceutical and biotech Sponsors in bringing their ocular drugs, as well as those that can potentially impact ophthalmic function, to market.” The ocular laboratory facilities at MPI Research will be housed within the Discovery Center.

Prior to starting Ophthy-DS in 2009, Dr. Jamison was a Principle Scientist in Ocular Biology at Pfizer where he developed in vivo drug exposure and disease pathology biomarkers for AMD, diabetic retinopathy, and glaucoma. Before that, he was a Senior Scientist III at Alcon Laboratories where his work contributed to the identification, optimization and selection of small molecule targets for AMD treatment which are currently in Phase III clinical trials. Dr. Jamison is a graduate of the University of Michigan Kellogg Eye center, where he received his PhD in biomedical engineering focusing on ERG changes in human and animal models of retinal degeneration.

MPI Research, with global headquarters in Mattawan, Michigan, is one of the world’s leading providers of comprehensive preclinical and early clinical research and development services. In addition to a comprehensive array of drug safety evaluation services, MPI Research also has a Discovery Center that offers experimental therapeutics (in vivo, molecular and cell-based assays), experimental surgery, molecular imaging, drug metabolism, pharmacokinetics, and immunology. The company also offers medical device evaluation, bioanalytical and analytical testing, among other services. Learn more about the company’s commitment to be the best at www.mpiresearch.com.